Committed contribution

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)The composition of other current assets is as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | September 24, 2022 |  | December 25, 2021 |
|  | (in thousands) |
| Prepaid income tax | $ | 87,038  |  |  | $ | 84,725  |  |
| Short-term investments | 950  |  |  | 1,063  |  |
| Restricted cash | 1,376  |  |  | 4,023  |  |
| Other receivables | 7,723  |  |  | 7,500  |  |
| Other current assets | $ | 97,087  |  |  | $ | 97,311  |  |

The composition of other assets is as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | September 24, 2022 |  | December 25, 2021 |
|  | (in thousands) |
| Venture capital investments | $ | 131,515  |  |  | $ | 149,640  |  |
| Strategic equity investments | 158,582  |  |  | 51,712  |  |
| Life insurance policies | 39,938  |  |  | 51,048  |  |
| Long-term pension assets | 33,491  |  |  | 39,582  |  |
| Other long-term income tax assets | 15,088  |  |  | 18,690  |  |
| Restricted cash | 1,100  |  |  | 1,077  |  |
| Other | 49,979  |  |  | 41,140  |  |
| Other assets | $ | 429,693  |  |  | $ | 352,889  |  |

The composition of other current liabilities is as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | September 24, 2022 |  | December 25, 2021 |
|  | (in thousands) |
| Current portion of operating lease right-of-use liabilities | $ | 44,613  |  |  | $ | 33,267  |  |
| Customer contract deposits | 76,904  |  |  | 59,512  |  |
| Accrued income taxes | 47,036  |  |  | 26,161  |  |
| Other | 13,341  |  |  | 18,701  |  |
| Other current liabilities | $ | 181,894  |  |  | $ | 137,641  |  |

The composition of other long-term liabilities is as follows:

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  |  |  |  |  |  |  |
|  | September 24, 2022 |  | December 25, 2021 |
|  | (in thousands) |
| Long-term pension liability, accrued executive supplemental life insurance retirement plan and deferred compensation plans | $ | 100,552  |  |  | $ | 104,944  |  |
| U.S. Transition Tax | 32,324  |  |  | 43,057  |  |
| Long-term deferred revenue | 24,161  |  |  | 20,578  |  |
| Other | 37,673  |  |  | 74,280  |  |
| Other long-term liabilities | $ | 194,710  |  |  | $ | 242,859  |  |

6. VENTURE CAPITAL AND STRATEGIC EQUITY INVESTMENTSVenture capital investments were $131.5 million and $149.6 million as of September 24, 2022 and December 25, 2021, respectively. The Company’s total commitment to the venture capital funds as of September 24, 2022 was $190.3 million, of which the Company funded $125.1 million through that date. The Company received distributions totaling $3.7 million and $10.2 million for the three months ended September 24, 2022 and September 25, 2021, respectively. The Company received distributions totaling $7.7 million and $37.7 million for the nine months ended September 24, 2022 and September 25, 2021, respectively. The Company recognized net gains on venture capital investments of $3.0 million and net losses of $10.3 million for the three months ended September 24, 2022 and September 25, 2021, respectively, both of which were driven primarily by publicly-held investments. The Company recognized net losses on venture capital investments of $20.1 million for the nine months ended 19
